RV

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: RV
• 英文别名: 2-[[2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoic acid
• 化学式: C₁₁H₂₃N₅O₃
• mdl: MFCD03019167
• 分子量: 273.33
• InChiKey: DAQIJMOLTMGJLO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.6
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  157
• 氢给体数：
  5
• 氢受体数：
  5

文献信息

• DIPEPTIDE-CONTAINING COMPOSITION FOR ORAL ADMINISTRATION
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1941896A1

  公开（公告）日：2008-07-09

  The present invention provides a composition for oral administration, which comprises at least one kind of dipeptide represented by the formula:         X-Y (wherein X represents alanyl, glycyl, arginyl, seryl, α-aspartyl or α-glutamyl, and Y represents valine, leucine or isoleucine), with an object of providing a composition for oral administration which is excellent in nutrition, pharmacological effect and gustation and comprises at least one kind selected from valine, leucine and isoleucine, or providing a composition for oral administration which is excellent in processing characteristics such as solubility and tableting property and comprises at least one kind selected from valine, leucine and isoleucine.

  本发明提供了一种口服组合物，它包含至少一种由式表示的二肽： X-Y (其中 X 代表丙氨酰、甘氨酰、精氨酰、丝氨酰、α-天冬氨酰或α-谷氨酰，Y 代表缬氨酸、亮氨酸或异亮氨酸），其目的是提供一种营养、药效和口感俱佳的口服组合物，该组合物至少包含一种选自缬氨酸、亮氨酸和异亮氨酸的二肽、或提供一种口服组合物，该组合物在加工特性（如溶解性和压片性能）方面非常出色，并包含至少一种选自缬氨酸、亮氨酸和异亮氨酸的成分。
• Reversibly inactivated acidified plasmin
  申请人：Talecris Biotherapeutics, Inc.

  公开号：EP1956082A1

  公开（公告）日：2008-08-13

  The present invention provides a fibrinolytic composition useful as a therapeutic for administration to a patient having a thrombotic occlusion. In one aspect of the present invention, the fibrinolytic composition comprises a reversibly inactivated acidified serine protease substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent. In another aspect of the invention, the fibrinolytic composition of the present invention comprises a reversibly inactivated acidified plasmin substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent.

  本发明提供了一种纤维蛋白溶解组合物，可用于治疗血栓性闭塞患者。在本发明的一个方面，本发明的纤维蛋白溶解组合物包括基本上不含纤溶酶原激活剂的可逆失活的酸化丝氨酸蛋白酶、低缓冲能力缓冲剂和可选的稳定剂。在本发明的另一方面，本发明的纤维蛋白溶解组合物包括基本上不含纤溶酶原激活剂的可逆失活的酸化纤溶酶、低缓冲能力缓冲剂，以及可选的稳定剂。
• Compositions and methods for modulating factor IX function
  申请人：The Children's Hospital of Philadelphia

  公开号：US10676731B2

  公开（公告）日：2020-06-09

  Factor IX/IXa variants and methods of use thereof are disclosed.

  已公开因子 IX/IXa 变体及其使用方法。
• Chimeric clotting factors
  申请人：Bioverativ Therapeutics Inc.

  公开号：US10968442B2

  公开（公告）日：2021-04-06

  Chimeric clotting factors which localize the therapeutic to sites of coagulation (e.g., by being targeted to platelets or being activatable at sites of coagulation), have reduced clearance rates, have improved manufacturability, have reduced thrombogenicity, have enhanced activity, or have more than one of these characteristics are described as are methods for making chimeric clotting factors and methods for improving hemostasis using these clotting factors.

  本文描述了将治疗药物定位在凝血部位（例如，通过靶向血小板或在凝血部位可激活）、降低清除率、改善可制造性、降低血栓形成性、增强活性或具有上述多个特征的嵌合凝血因子，以及制造嵌合凝血因子的方法和使用这些凝血因子改善止血的方法。
• Process for the production of a reversibly inactive acidified plasmin composition
  申请人：——

  公开号：US20020192794A1

  公开（公告）日：2002-12-19

  Disclosed is both a process for producing a reversibly inactive acidified plasmin by activating plasminogen and a process for producing a purified plasminogen. The produced plasmin is isolated and stored with a low pH-buffering capacity agent to provide a substantially stable formulation. The purified plasminogen is typically purified from a fraction obtained in the separation of immunoglobulin from Fraction II+III chromatographic process and eluded at a low pH. The reversibly inactive acidified plasmin may be used in the administration of a thrombolytic therapy.

  所公开的是一种通过活化纤溶酶原生产可逆性非活性酸化纤溶酶原的工艺和一种生产纯化纤溶酶原的工艺。生产出的血浆蛋白酶与低 pH 缓冲剂一起分离和储存，以提供一种基本稳定的制剂。纯化的纤溶酶原通常是从免疫球蛋白从Ⅱ+Ⅲ色谱分离过程中得到的馏分中纯化出来的，并在低pH值条件下洗脱。可逆的无活性酸化血浆蛋白酶可用于溶栓治疗。